Evidence map›Paper›PMID 41405810›Full record

ArticleInternational journal of hematology2026

Talquetamab in Japanese patients with relapsed/refractory multiple myeloma in the MonumenTAL-1 study.

Shigeki Ito, Yoshiaki Kuroda, Kazutaka Sunami, Kosei Matsue, Kazunori Imada, Hideto Tamura, Ei Fujikawa, Hiroshi Yamazaki, Mikihiro Takamoto, Lixia Pei and 6 more

2 registry-linked trialsAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03399799 phase1active not recruitingnot on this map

64407564MMY1001: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

TypeinterventionalSponsorJanssen Research & Development, LLCRan2017 to 2027Enrolled279ConditionsHematological MalignanciesArmsTalquetamab
NCT04634552 phase2recruitingnot on this map

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

TypeinterventionalSponsorJanssen Research & Development, LLCRan2021 to 2029Enrolled510ConditionsHematological MalignanciesArmsTalquetamab
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shigeki ItoIwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba, Iwate, 028-3695, Japan. shigei@iwate-med.ac.jp.ORCID http://orcid.org/0000-0002-3899-6603
Yoshiaki KurodaNHO, Hiroshimanishi Medical Center, Hiroshima, Japan.
Kazutaka SunamiNHO, Okayama Medical Center, Okayama, Japan.
Kosei MatsueKameda Medical Center, Kamogawa, Chiba Prefecture, Japan.
Kazunori ImadaJapanese Red Cross Osaka Hospital, Osaka, Japan.
Hideto TamuraDokkyo Medical University Saitama Medical Center, Saitama, Japan.
Ei FujikawaJohnson & Johnson, Tokyo, Japan.
Hiroshi YamazakiJohnson & Johnson, Tokyo, Japan.
Mikihiro TakamotoJohnson & Johnson, Tokyo, Japan.
Lixia PeiJohnson & Johnson, Raritan, NJ, USA.
Xiang QinJohnson & Johnson, Spring House, PA, USA.
Tara J MastersonJohnson & Johnson, Spring House, PA, USA.
Michela CampagnaJohnson & Johnson, Madrid, Spain.
Veronique VreysJohnson & Johnson, Beerse, Belgium.
Bonnie W LauJohnson & Johnson, Spring House, PA, USA.
Yasushi TakamatsuFukuoka University Hospital, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Talquetamab is the first G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody approved for relapsed/refractory multiple myeloma (RRMM). We report the first efficacy and safety results of talquetamab in Japanese patients enrolled as a separate cohort in the global MonumenTAL-1 study. Between July 2022 and December 2023, 36 patients were enrolled and received 0.4 mg/kg talquetamab weekly. Median follow-up was 13.4 months. The overall response rate was 77.8% (55.6% achieved complete response or better). Median time to first response was 1.2 months. Twelve-month duration of response, progression-free survival, and overall survival rates were 66.4%, 56.3%, and 74.1%, respectively. On-target, off-tumor adverse events (AEs), including taste-, skin- (non-rash), nail-, and rash-related AEs, were common (80.6%, 66.7%, 55.6%, and 36.1%, respectively) and mostly grade 1/2. Cytokine release syndrome occurred in 75.0% of patients; all events were grade 1/2. The rate of infection was 52.8%; the rate of grade 3/4 infection was 16.7% (one led to death [pneumonia]). One patient discontinued talquetamab and three patients died due to AEs. Results were generally consistent with the global MonumenTAL-1 population, demonstrating talquetamab as an important novel treatment for Japanese patients with RRMM. Clinical trial registration number: NCT03399799/NCT04634552.

Indexed as

Antibodies, BispecificMultiple MyelomaAdultAgedAged, 80 and overEast Asian PeopleFemaleHumansJapanMaleMiddle AgedRecurrenceSurvival RateTreatment OutcomeAntibodies, BispecifictalquetamabBispecific antibodyGPRC5DJapanese patientsMultiple myelomaTalquetamab

Identifiers

PMID41405810
PMCPMC13083461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.